Search

Your search keyword '"Omran, Wael"' showing total 8 results
Start Over Author "Omran, Wael"
8 results on '"Omran, Wael"'

1. Circulating MicroRNAs as Biomarker for Vessel-Associated Retinal Diseases

Author

Dähmcke, Merlin, primary, Busch, Martin, additional, Pfeil, Johanna M., additional, Brauckmann, Tara, additional, Schulz, Daniel, additional, Omran, Wael, additional, Morawiec-Kisiel, Ewa, additional, Wähler, Fabienne, additional, Paul, Sebastian, additional, Tayar, Allam, additional, Bründer, Marie-Christine, additional, Grundel, Bastian, additional, and Stahl, Andreas, additional

Published
2023
Full Text
View/download PDF

2. Anti‐drug antibodies to brolucizumab and ranibizumab in serum and vitreous of patients with ocular disease

Author

Busch, Martin, primary, Pfeil, Johanna M., additional, Dähmcke, Merlin, additional, Brauckmann, Tara, additional, Großjohann, Rico, additional, Chisci, Viola, additional, Hunfeld, Elisabeth, additional, Eilts, Sonja, additional, Omran, Wael, additional, Morawiec‐Kisiel, Ewa, additional, Schulz, Daniel, additional, Paul, Sebastian, additional, Tayar, Allam, additional, Bründer, Marie‐Christine, additional, Grundel, Bastian, additional, Küstner, Martin, additional, and Stahl, Andreas, additional

Published
2022
Full Text
View/download PDF

5. Primary treatment of acromegaly with high-dose lanreotide: a case series

Author

Cordes Uwe, Both Stefan, Wuster Christian, Omran Wael, and Reisch Robert

Subjects
Medicine
Abstract

Abstract Introduction The first-line treatment for acromegaly is transsphenoidal surgery. In approximately 50% of patients, however, a cure is not possible with surgery and alternatives are needed. Somatostatin analog therapy is the recommended first-line treatment in patients with such cases. Here we provide the first report of a high-dose lanreotide primary therapy in patients with acromegaly. Case presentation Six patients who were not suitable for surgery were given 60 mg of lanreotide (Autogel®) every four weeks. All patients were German nationals and Caucasian. When the response of our patients was unsatisfactory, the dose was increased sequentially to 90 mg every four weeks, 120 mg every four weeks, 120 mg every three weeks and 180 mg every three weeks. Treatment duration was 12 to 24 months. In all cases, the lanreotide dose was 120 mg every 4 weeks or higher. In five of our patients, growth hormone (GH) levels were successfully reduced (in three patients GH Tumor shrinkage or degeneration was observed in the five responding patients. No drug-related adverse events were noted. Conclusions These results suggest that lanreotide at high doses of 120 mg every four weeks or more is an effective first-line therapy for patients with acromegaly that surgery alone cannot treat.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results